financetom
Business
financetom
/
Business
/
Deutsche Bank Gives Its Outlook of Bank of England Policy Action
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Deutsche Bank Gives Its Outlook of Bank of England Policy Action
Oct 22, 2024 12:10 PM

07:38 AM EDT, 10/22/2024 (MT Newswires) -- Deutsche Bank said it now shifted its call to a two-stage rate-cutting cycle at the Bank of England.

In Stage 1, the bank expects the BoE's Monetary Policy Committee to move the Bank Rate sequentially over the next few months, taking the Bank Rate down to 3.75% by May 2025.

Following that, in Stage 2, Deutsche Bank estimates the MPC to move to a quarterly pace of rate cuts all the way down to 3% -- the mid-point of the bank's medium-term neutral rate estimates.

The risk of 50bps rate cuts has risen in recent weeks, but the conditions for 'forceful' rate cuts have yet to be met, and the window for any outsized rate cuts is likely to be small, stated Deutsche Bank.

Importantly, the bank still sees risks skewed to a higher terminal rate -- especially in light of growing expectations of looser fiscal policy in the British Fall Budget -- with the MPC potentially pausing following Stage 1 of the easing cycle, or at 3.75%.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-UK's Competition Regulator Starts Probe Into Arla-Volac Deal
BRIEF-UK's Competition Regulator Starts Probe Into Arla-Volac Deal
Sep 21, 2024
Sept 18 (Reuters) - UK's Competition and Markets Authority: * COMPETITION AND MKTS - ARLA FOODS INGREDIENTS / VOLAC WHEY NUTRITION: STC * UK'S CMA SAYS START OF CMA MERGER INVESTIGATION: ARLA FOODS INGREDIENTS/VOLAC WHEY NUTRITION * UK'S CMA SAYS DEADLINE OF 13 NOVEMBER 2024 FOR ITS PHASE 1 DECISION. Source text for Eikon: Further company coverage: ...
TG Therapeutics Reports 30-Minute BRIUMVI Infusions Well Tolerated in Relapsing Multiple Sclerosis Trial
TG Therapeutics Reports 30-Minute BRIUMVI Infusions Well Tolerated in Relapsing Multiple Sclerosis Trial
Sep 21, 2024
08:25 AM EDT, 09/18/2024 (MT Newswires) -- TG Therapeutics ( TGTX ) said Wednesday that updated data from a phase 3b trial showed that rapid 30-minute infusions of BRIUMVI (ublituximab) are well tolerated in patients suffering from relapsing forms of multiple sclerosis. The trial demonstrated that 450 mg of BRIUMVI administered in 30 minutes at week 24 was completed without...
Organon to buy skin therapy developer Dermavant for up to $1.2 billion
Organon to buy skin therapy developer Dermavant for up to $1.2 billion
Sep 21, 2024
Sept 18 (Reuters) - Healthcare company Organon said on Wednesday it has agreed to acquire skin therapy developer Dermavant, a unit of Roivant, for up to $1.2 billion. Organon will make an upfront payment of $175 million, as well as milestone payments of $75 million and up to $950 million upon achievement of certain commercial milestones. Dermavant's VTAMA psoriasis cream...
BMO on The Day Ahead in Canada
BMO on The Day Ahead in Canada
Sep 21, 2024
07:52 AM EDT, 09/18/2024 (MT Newswires) -- On the Canadian docket Wednesday at 1:30 p.m. ET, Bank of Montreal (BMO) noted that the Summary of Deliberations from the Bank of Canada's Sept. 4 policy meeting, which saw a third consecutive 25 bp rate cut, will be scoured for any clues on what it would take to prompt more aggressive easing....
Copyright 2023-2026 - www.financetom.com All Rights Reserved